Market Research Report
50 Key Biopharmaceutical and Biotechnology Companies
|Published by||Kalorama Information||Product code||594917|
|Published||Content info||201 Pages
Delivery time: 1-2 business days
|50 Key Biopharmaceutical and Biotechnology Companies|
|Published: December 12, 2017||Content info: 201 Pages||
50 Key Biopharmaceutical and Biotechnology Companies is a comprehensive look at the top 50 companies that are shaping the biotherapeutics market in 2017 and beyond. The top 50 companies in this report were chosen for a variety of reasons, including sales of marketed biopharmaceutical products, innovation in biotherapeutics, and unique additions to the market, either marketed products or products in development.
50 Key Biopharmaceutical and Biotechnology Companies includes large traditional pharma powerhouses such as Pfizer, Novartis, Roche, Merck, GSK, Bristol-Myers Squibb, Bayer, and others; but it also includes smaller niche companies such as Genmab, Seattle Genetics, etc. In addition, it includes leading biopharmaceuticals such as Amgen and Biogen, and leading biotech companies such as Qiagen, Alexion, Agilent, Waters Co and others.
Biopharmaceuticals are therapeutic agents intended to treat symptoms and/or underlying causes of a variety of disorders and diseases. They have been a growing part of the pharmaceutical landscape since the early 1980s and is, today, one of the fastest growing areas in the pharmaceutical industry, growing at an average rate of 12%-15% over the past two years. Today, there are many biologics in the approval pipeline and it has been projected that over 65% of drugs approved for the marketplace in 2017 will be the result of biotechnology. Biopharmaceuticals hold great promise for treating some of the most intractable medical conditions such as cancer and autoimmune disease.
Biotechnology is the applied knowledge of biology, it seeks to duplicate or change the function of a living cell, so it will work in a more predictable and controllable way. The biotechnology industry uses advances in genetics research to develop products for human diseases and conditions.
Biotech opportunities largely mirror those in the pharmaceutical industry. The key difference is that biotech firms are much more focused on research because they are still developing their initial products. Biotech firms tend to expand their marketing and sales forces when and if a viable product nears FDA approval.
50 Key Biopharmaceutical and Biotechnology Companies profiles these market leaders in-depth, presenting detailed information about each company, including:
SCOPE AND METHODOLOGY
BIOPHARMACEUTICALS AND BIOTHERAPEUTICS
REGULATIONS FOR BIOPHARMACEUTICALS
AGILENT TECHNOLOGIES INC.
ALEXION PHARMACEUTICALS INC
BERRY GENOMICS CO LTD.
BIOMARIN PHARMACEUTICAL INC
BRISTOL MYERS SQUIBB
CRISPR THERAPEUTICS AG
DR. REDDY'S LABORATORIES LIMITED
ELI LILLY & CO
ENZO BIOCHEM, INC
GRIFOLS INTERNATIONAL S.A.
JOHNSON & JOHNSON
MERCK & CO, INC.
NOVARTIS INTERNATIONAL AG
NOVO NORDISK A/S
OXFORD NANOPORE TECHNOLOGIES
PERKIN ELMER, INC
PRECISION BIOSCIENCES INC.
SEATTLE GENETICS, INC.
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
THERMO FISHER SCIENTIFIC, INC
UNITED THERAPEUTICS CORPORATION